Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Freegold Intersects 1.53 g/t Au over 191.3m in infill drilling at Golden Summit (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Medexus Pharmaceuticals Inc
T.MDP
Alternate Symbol(s):
MEDXF
Healthcare
Drug Manufacturers - Specialty & Generic
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation...
of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxac...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (TSX:MDP)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Next
(1588)
•••
Possibleidiot01
X
Post by
Possibleidiot01
on Mar 19, 2025 11:30am
smallcapdiscoveries.com interview
https://www.youtube.com/watch?v=oTkppTgGhd4
(8)
•••
MintyZyn
X
Comment by
MintyZyn
on Mar 10, 2025 11:09am
RE:Assessment
I screened these guys the other day. Look attractively valued for what's ahead this year. Started a position.
DiagnosTear Announces Clinical Study with AlyaTec
posted Dec 04, 2025 9:00am by
Diagnostear Technologies Inc
-
|
TeaRx™ Red Eye is being developed as the first rapid, multi-biomarker diagnostic test designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis at the point of care. These three conditions drive hundreds of millions of clinic visits every year, yet misdiagnosis remains widespread due to the absence of fast, accurate testing. TeaRx™ aims to change that with a simple test that delivers clinical answers in minutes. ...read more
(5997)
•••
retiredcf
X
Post by
retiredcf
on Feb 10, 2025 10:42am
Assessment
20% below the financing level + this = just opened a small position. GLTA Would welcome your analysis on this small cap. It has recently received some positive reports, appears to be cash flow
...more
(30)
•••
thedave2006
X
Post by
thedave2006
on Feb 06, 2025 3:01pm
$4 financing
Houston, we have a problem?
(5)
•••
SushiGobbler
X
Post by
SushiGobbler
on Jan 23, 2025 10:23am
FDA Approval of GRAFAPEX, 100m rev projected~5yr
https://ca.finance.yahoo.com/news/medexus-announces-fda-approval-grafapex-155900222.html
(1326)
•••
lscfa
X
Post by
lscfa
on Nov 08, 2024 1:02pm
$100M shelf prospectus filed
On sedar.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 18, 2024 5:01pm
New Press Release - Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 06, 2024 10:42am
New Press Release - Canadian Investment Regulatory Organization Trading Halt - MDP
TORONTO, June 6, 2024 /CNW/ - The following issues have been halted by CIRO:Company: Medexus Pharmaceuticals Inc.TSX Symbol: MDPAll Issues: YesReason: Pending NewsHalt Time (ET): 10:03 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 06, 2024 10:35am
New Press Release - Canadian Investment Regulatory Organization Trade Resumption - MDP
TORONTO, June 6, 2024 /CNW/ - Trading resumes in:Company: Medexus Pharmaceuticals Inc.TSX Symbol: MDPAll Issues: YesResumption (ET): 11:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 06, 2024 10:19am
New Press Release - FDA Accepts for Review Treosulfan NDA Resubmission
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for...
read article.
(102)
•••
Napcoo
X
Comment by
Napcoo
on May 21, 2024 11:11pm
RE:RE:This article favor Treo over busulfan
Published on May 26, 2022, announced NDA resubmission on July 25, 2022, FDA rejected on September x https://onlinelibrary.wiley.com/doi/10.1002/ajh.26620
(102)
•••
Napcoo
X
Comment by
Napcoo
on May 21, 2024 10:47pm
RE:RE:RE:This article favor Treo over busulfan
On treosulfan, we are pleased to report that the data collection phase of medac's effort to respond to the FDA's information requests on treosulfan is now complete," Mr d'Entremont
...more
(102)
•••
Napcoo
X
Comment by
Napcoo
on May 21, 2024 10:40pm
RE:RE:This article favor Treo over busulfan
An NDA includes all animal and human data and analyses of the data, as well as information about how the drug behaves in the body and how it is manufactured. When an NDA comes in, the FDA has 60 days
...more
(102)
•••
Napcoo
X
Comment by
Napcoo
on May 21, 2024 10:26pm
RE:This article favor Treo over busulfan
The second published by nature favor Treo https://www.nature.com/articles/s41409-024-02269-4
(102)
•••
Napcoo
X
Post by
Napcoo
on May 21, 2024 10:12pm
This article favor Treo over busulfan
https://www.nature.com/articles/s41409-023-02135-9
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Sorrento Resources Provides Update on Exploration on Rodgers Cove Project, Newfoundland
A tungsten producer and developer in Portugal, South Korea & Spain on track to become a top supplier
DiagnosTear Announces Clinical Study to Advance Analytical Validation & FDA Submission Pathway of TeaRx(TM)
A Company Focused on Developing Functional Healthier “Better For You” Foods
Building Momentum in One of the World's Most Prospective Copper Regions